Oncologists near Rutherford, NJ

Biography: Dr. Adriana Malone, MD is a Hematology Specialist who practices in New York, NY. She is 52 years old and has been practicing for 25 years. Dr. Adriana Malone, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Krzysztof Misiukiewicz, MD is a Hematology Specialist who practices in New York, NY. He is 52 years old. Dr. Krzysztof Misiukiewicz, MD is affiliated with Mount Sinai Hospital.

Care Philosophy: Multidisciplinary, respectful care of patients with GU cancers

Care Philosophy: As an oncologist, I believe providing the best state of the art treatment available for our patients. Our team of cancer specialists will ensure you will receive the best possible care.

Biography: Dr. Marina Kremyanskaya, MD is a Hematology Specialist who practices in New York, NY. She is 49 years old. Dr. Marina Kremyanskaya, MD is affiliated with Mount Sinai Hospital.

Care Philosophy: I believe in treating the patients as a whole rather than their ailment only. As a pediatrician, I like to partner with the family to care for the patient as it is important since the patient's ailment doesn't affect patient herself but the whole family.

Biography: James McKiernan, MD, is the John K. Lattimer Professor of Urology, and CEO, of ColumbiaDoctors. He also is the interim dean of Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues. For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer.

Biography: Dr. James Lee is an internationally recognized endocrine surgeon who specializes in the care of patients with thyroid, parathyroid, and adrenal disorders. Dr. Lee is the Chief of Endocrine Surgery and the Edwin K. and Anne C. Weisskopf Professor of Surgical Oncology at Columbia University and the Physician Director of the Endocrine Service Line at the NY Presbyterian Hospital. He serves as Co-Director of the multidisciplinary Columbia Thyroid Center, Parathyroid Center, and Adrenal Center. He has been rated as one of the Best Doctors in America and is one of the highest volume endocrine surgeons in the country. Dr. Lee received his medical degree from Columbia University's College of Physicians and Surgeons, completed his residency in General Surgery at Columbia and went on to a fellowship in Endocrine Surgery at the University of California, San Francisco. Dr. Lee is actively involved in the leadership of Endocrine Surgery at the national and international level. He serves on the Executive Council of the American Association of Endocrine Surgeons and Standing Faculty of the international Endocrine Surgery University. He co-created the inaugural Postgraduate Course in Endocrine Surgery at the American College of Surgeons and is a featured lecturer in the biannual Masters of Endocrine Surgery Course. He has authored over 100 articles and book chapters, including the AAES Parathyroidectomy Guidelines which sets the international standard for the care of patients with parathyroid disease. He is also the Co-Editor of Surgical Endocrinopathies and the Founding Figures which details state of the art care for patients with endocrine disorders as well as the rich history of discovery in the field. Dr. Lee has given over 100 invited lectures and visiting professorships at institutions around the world. He has travelled extensively to teach other endocrine surgeons advanced techniques such as minimally invasive thyroid and parathyroid surgery as well as laparoscopic retroperitoneal adrenalectomy. He has mentored dozens of clinical and research fellows over his career, many of whom are now leaders in their own institutions and abroad. Dr. Lee also serves as the Vice Chair of New Media in the Columbia University Department of Surgery and Chair of the ColumbiaDoctors Communications Committee. In this role, he oversees the digital strategy for multiple groups across the medical center with the mission of providing the highest quality education on health and wellness to the global audience.

Care Philosophy: I treat each person as a unique individual. I get to know that person and listen to the medical issue(s) that led him/her to see me. I spend time in conversation and examination to gather the information necessary for a diagnosis and treatment. I discuss the management options so that we can jointly select the appropriate treatment. Every question is welcomed. I enjoy learning about each person and sharing the benefit of my expertise. I hold sacred the trust placed in my care.

Biography: Dr. Kevin Clarke, MD is an Oncology Specialist who practices in Newark, NJ. He is 51 years old. Dr. Kevin Clarke, MD is affiliated with Newark Beth Israel Medical Center.

Biography: Dr. Valentin Kolev, MD is an Oncology Specialist who practices in New York, NY. He is 50 years old. Dr. Valentin Kolev, MD is affiliated with Mount Sinai Queens, Mount Sinai Brooklyn and Mount Sinai Morningside.

Biography: Dr. Diana Kirke, MD is an Otolaryngology (Ear, Nose /amp Throat) Specialist who practices in New York, NY. She is 46 years old and has been practicing for 20 years. Dr. Diana Kirke, MD is affiliated with Mount Sinai Morningside, Mount Sinai Queens and Mount Sinai Hospital.

Biography: Dr. Feldman is an Assistant Professor of Medicine in the Division of Cardiology of the Department of Medicine at Weill Cornell Medical College and an Attending Physician at New York Presbyterian-Weill Cornell Medical Center.Dr. Feldman grew up in Framingham, Massachusetts and completed her undergraduate studies at the University of Pennsylvania. She earned her medical degree from Boston University School of Medicine, completed Internal Medicine residency at Beth Israel Deaconess Medical Center/Harvard Medical School, where she completed the Clinician Educator Track, fellowship in Cardiovascular Disease at Boston Medical Center/Boston University School of Medicine, and an additional fellowship in Cardio-Oncology at Memorial Sloan Kettering Cancer Center. After training, she founded and directed the Cardio-Oncology and Cardiac Amyloidosis programs at Rutgers New Jersey Medical School/University Hospital. In 2023, she joined the Cardiology Division at New York-Presbyterian/Weill Cornell Medical College as a full-time faculty member where she provides expertise in cardio-oncology, cardiac imaging, and medical education. She serves as the Director of the Cardio-Oncology program.Dr. Feldman is board certified in Internal Medicine, Cardiovascular Diseases, Echocardiography, Nuclear Cardiology, and Cardio-Oncology. She is a fellow of the American College of Cardiology, and a member of the American Heart Association, American Society of Nuclear Cardiology, and the International Society of Cardio-Oncology.

Care Philosophy: At Moffitt Cancer Center, we are working tirelessly in the areas of patient care, research and education to advance one step further in fighting cancer. As a National Cancer Institute-designated Comprehensive Cancer Center, we are committed to the health and safety of our patients and dedicated to providing expert cancer care. From enhanced quality of life to complete remission, Moffitt is Florida's top choice aiming to achieve the best outcome for each patient.

Biography: Dr. Barbara T. Ma, is an Assistant Professor of Medicine at Weill Cornell Medicine and an Assistant Attending Physician at New York Presbyterian Hospital. Dr. Ma graduated with B.S. in Biomedical Engineering and M.S. in Biotechnology from Johns Hopkins University. She received her medical degree from New York Medical College. She completed her internal medicine training at Georgetown University Hospital and fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medicine, where she also served as a chief fellow. Dr. Ma cares for patients with skin cancers, including melanoma. Her research focus is optimizing immunotherapy treatments for solid tumor patients with special interest on immunotherapy toxicities. She heads the Phase I unit and leads Cellular Therapy for Solid Tumors at Cornell. Dr. Ma is a recipient of the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award. She is a member of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Golden Humanism Honor Society (GHHS), and Society for Immunotherapy and Translational Research in Cancer.

Care Philosophy: My goal, as a colon and rectal surgeon and as a surgical oncologist is to help my patients make informed decisions in their care and understand their disease process and treatment options, both surgical and non-surgical. I hope to help my patients find a better quality of life and to help them through their surgical experience (when necessary). I am lucky to work with a world renowned group of multidisciplinary specialists to help promote a multifaceted treatment plan for my patients, including radiation oncologists, medical oncologists, radiologists, pathologists, gastroenterologists, pelvic floor specialists, urologists, and interventional radiologists.

Care Philosophy: I realize how scary it can be to receive a life-threatening diagnosis, and firmly believe in taking the time to clearly communicate with my patients about the nature of their disease and their various treatment options. This can not only vastly improve our patients' experiences, but also their treatment outcomes, as an educated patient is able to make informed decisions about care and reclaim some of the autonomy that can be lost when coping with a cancer diagnosis. In the midst of all the cutting-edge science and technology that we offer, I find it extremely important to remember that it is the patient who is the center of it all. I genuinely care about my patients, and instilling a sense of hope, sharing a laugh, or a kind word can be as important as all the medical advances and state-of-the-art science.

Care Philosophy: I am a physician-scientist working clinically and in the laboratory to develop curative treatment strategies for blood cancers.

Biography: Dr. Cora Sternberg is a leading international researcher and world expert in the field of medical oncology, genitourinary (GU) cancers, and drug development. As a key opinion leader in three different types of genitourinary cancers, Dr. Sternberg isknown for her influential work in developing novel therapies and targeted agents for the treatment of prostate, renal and bladder cancers.Dr. Sternberg helped develop the original M-VAC chemotherapy regimen, as well as the double-dose/high-dose/accelerated-dose M-VAC chemotherapy regimens in bladder and urothelial cancers. These treatments are the gold standard, saving many lives and decreasing suffering in patientswith these diseases.Additionally, Dr. Sternberg has served as principal investigator or been involved in numerous practice-changing studies for prostate cancer. These research efforts have led to the FDA approvals of abiraterone acetate and enzalutamide in advanced prostate cancer. Most recently, her publication in the New England Journal of Medicine (NEJM) demonstrated dramatic improvements in metastasis-free survival (MFS) in men with castration resistant prostate cancer (CRPC) without evidence of metastatic disease, but at high risk of developing metastases, a population for whom there were previously no approved therapeutics. This research led to the approval of enzalutamide in the M0 CRPC patient population.Dr. Sternberg has been instrumental in the development of the drug Pazopanib, an antiangiogenic targeted therapy, for advanced clear cell renal cell carcinoma. Dr. Sternberg served as lead investigator in the large phase 3 international study that demonstrated the efficacy, safety and tolerability of this drug in patients with metastatic kidney cancer, culminating in the FDA approval. She has also participated in the development of other antiagiogenic agents such as sunitinib, cabozantinib, tivozanib and dovitinib to treat renal cell cancer.At Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Sternberg will facilitate the continued growth and development of clinical and translational research programs in genitourinary (GU) malignancies, with a particular emphasis on expanding the breadth and depth of clinical and translational research. AsClinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens. In addition to providing her clinical and research expertise in genitourinary oncology, Dr. Sternberg will work closely with Olivier Elemento, PhD, renowned computational biologist and Director of the EIPM, to develop novel strategies and apply precision oncology to optimize cancer prevention, detection and treatment across a variety of tumor types.Dr. Sternberg previously served as Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy, and adjunct Professor of Oncology at La Sapienza University in Rome. A graduate of the University of Pennsylvania undergraduate and medical schools, Dr. Sternberg completed her fellowship and previously was on staff at Memorial Sloan Kettering Cancer Center.Dr. Sternberg has published approximately 400 articles in peer-reviewed publications,including more than 100 first-authored articles. She has co-edited six textbooks, guest edited six others, and has published over 80 book chapters. Dr. Sternberg has lectured extensively at universities and cancer symposia worldwide, having given approximately 750 invited talks atprestigious international venues.Throughout her career, she has served on the editorial boards of Critical Reviews in Hematology and Oncology, Annals of Oncology, and the Journal of Clinical Oncology, and she currently serves on the editorial boards of Oncology, European Urology, the Harvard Medical School Annual Report on Prostate Diseases, Kidney Cancer, Nature Clinical Practice Urology, and European Urology Oncology. Dr. Sternberg also serves as Reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, the Lancet Oncology and others.She currently serves as the Solid Tumor Editor for Critical Reviews in Hematology and Oncology, Section Editor for Urologic Oncology, Associate Editor for Bladder Cancer Clinical Trials Corner, Associate Editor and Genitourinary Oncology Editor for ESMO Open-Cancer Horizons, and Associate Editor for Frontiers in Oncology. Additionally, Dr. Sternberg previously served as Oncology Editor for the British Journal of Urology, Section Editor for Urologic Oncology, and Genitourinary Editor for the European Journal of Cancer.Dr. Sternberg's leadership in the field is further exemplified by the numerous international committees on which she has served. She was elected to three consecutive terms as Board Member and Executive Board Member of the European Organization for Research and Treatment of Cancer (EORTC) and elected to the nominating committee of the American Society of Clinical Oncology (ASCO) board of directors, currently serving a 3-year term.This document has been edited with the instant web content composer which can be found at htmleditor.tools - give it a try.

Biography: Nicole Lamanna, MD, is an Associate Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Dr. Lamanna is a hematologist/oncologist whose research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia. She is an experienced clinical investigator and her research focus has been the development of combination therapies that include chemoimmunotherapy, immunomodulatory drugs, novel kinase inhibitors and monoclonal antibodies. She also is working to find active, safer therapies for older patients with these diseases. She earned her medical degree from Albert Einstein College of Medicine and completed her fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.

Biography: Dr. Anupama Goel, MD is a Hematology Specialist who practices in New York, NY. She is 52 years old and has been practicing for 28 years. Dr. Anupama Goel, MD is affiliated with Mount Sinai Hospital and Mount Sinai Morningside.

Care Philosophy: Dr. Abo is committed to his patients and providing the highest quality of comprehensive compassionate care. He strongly believes in a partnership with his patients, working together to ensure they understand their clinical situation, treatment plan and what their expectations are in managing their care. Working collaboratively with other medical specialists and staying informed on the latest research, proven treatments, and clinical trials ensures my patients have the best chance of obtaining optimal outcomes.

Care Philosophy: Where Care and Compassion Matters

Biography: Dr. Bret Taback is a nationally recognized surgical oncologist in the New York-Presbyterian/Columbia University Irving Medical Center department of surgery. Dr. Taback is a leader in the clinical management of melanoma, sarcoma and skin/soft tissue tumor surgery. Dr. Taback is the Director of the Melanoma and Sarcoma Program and Director of the Breast Surgery Fellowship. Dr. Taback received his MD degree at Tufts University School of Medicine in Boston , and completed his general surgery residency at Brown University, Rhode Island Hospital. During that time he completed a Basic Science Research Fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston. Following this, he completed a fellowship in Complex Surgical Oncology at the John Wayne Cancer Institute, Santa Monica, California. Dr. Taback is a member of a number of organizations and societies including Society of Surgical Oncology, American Society of Clinical Oncology and the American Association for Cancer Research. He is also a Fellow of the American College of Surgeons. He has published and authored numerous peer review manuscripts, abstracts and presentations, as well as book chapters over the years in notable publications such as Annals of Surgery, Annals of Surgical Oncology, Cancer Research, Clinical Cancer Research and the Journal of the National Cancer Institute. He is a clinical investigator with SWOG and Alliance for clinical trials. Dr. Taback has served on numerous hospital committees including tumor boards, Institutional Review Boards, Oncology Operations Council and is the American College of Surgeon's Commission on Cancer Physician Liaison for NYP Hospital. Most recently, Dr. Taback is a noted Castle Connolly Top Doctor.

Biography: Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute. Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer.

Biography: Dr. Monica Hayes, MD is an Oncology Specialist who practices in New York, NY. She is 54 years old and has been practicing for 28 years. Dr. Monica Hayes, MD is affiliated with Mount Sinai Queens, Mount Sinai Morningside and Mount Sinai Brooklyn.

Biography: Dr. Sitamahala Yerramalli, MD is an Oncology Specialist who practices in Belleville, NJ. She is 72 years old and has been practicing for 50 years. Dr. Sitamahala Yerramalli, MD is affiliated with Clara Maass Medical Center.

Biography: Dr. Samantha Cohen, MD is an Oncology Specialist who practices in New York, NY. She is 53 years old and has been practicing for 21 years. Dr. Samantha Cohen, MD is affiliated with Mount Sinai Morningside, Mount Sinai Brooklyn and Mount Sinai Queens.

Biography: Dr. Stephanie Blank, MD is an Oncology Specialist who practices in New York, NY. She is 59 years old and has been practicing for 31 years. Dr. Stephanie Blank, MD is affiliated with Mount Sinai Morningside, Mount Sinai Queens and Mount Sinai Brooklyn.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Care Philosophy: I have always been exquisitely sensitive to the cultural and emotional aspects of being ill. Fortunately, due to innovative treatments as well as a change in the medical mindset, we are now able to approach cancer therapy with a goal of maximizing quality of life while at the same time controlling disease. In many areas of oncology, especially in advanced, difficult to treat cancers and metastatic disease, the key to pursuing therapy is individualizing treatment to the patient's personal ability to withstand therapy. Thinking of cancer as a chronic disease and gearing therapies to be sustainable and effective is among one of my most important goals as I move forward with our clinical research and cancer treatment programs.

Biography: Dr. Surabhi Batra, MD is a Pediatric Hematology-Oncology Specialist who practices in Newark, NJ. She is 43 years old. Dr. Surabhi Batra, MD is affiliated with Cooperman Barnabas Medical Center and Newark Beth Israel Medical Center.

Biography: Dr. Harini Rao, MD is an Oncology Specialist who practices in Newark, NJ. She is 45 years old and has been practicing for 17 years. Dr. Harini Rao, MD is affiliated with Cooperman Barnabas Medical Center and Newark Beth Israel Medical Center.

Care Philosophy: Dr. Phillips embraces the multi-disciplinary approach to cancer care at Cooperman Barnabas Medical Center. She works collaboratively with the members of the oncology team to ensure access to state of the art treatments and optimal patient outcomes.

Biography: Dr. Marianna Debenedictis, MD is a Pediatric Hematology-Oncology Specialist who practices in Newark, NJ. She is 44 years old and has been practicing for 11 years. Dr. Marianna Debenedictis, MD is affiliated with Newark Beth Israel Medical Center.

Biography: Andrew Eisenberger graduated from Columbia University with a BA in Philosophy in 1992 and received his MD from Albert Einstein College of Medicine in 2001. Dr. Eisenberger did his residency in internal medicine at Montefiore Medical Center, where he served for a year as chief resident. He then completed his fellowship in Hematology/Oncology at New York Presbyterian Hospital/Columbia University Medical Center. Dr. Eisenberger embraces his role as a medical educator: for medical students, physicians in training, colleagues and patients alike. The Columbia University Vagelos School of Physicians and Surgeons' Hematology course has been under his leadership for more than a decade, and he recently became an associate program director of the University's Hematology/Oncology post-doctoral fellowship program. Dr. Eisenberger was inducted into the Medical Center's Academy of Clinic Excellence in 2018. His clinical practice currently focuses on the diagnosis and management of complex bleeding and clotting disorders, particularly in unique populations such as pregnant women and critically ill hospitalized patients. He also has extensive experience with difficult-to-manage blood disorders including antiphospholipid antibody syndrome (APLS), heparin-induced thrombocytopenia (HIT), immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), thrombotic thrombocytopenic purpura (TTP), hematologic complications of solid organ transplantation and myeloproliferative neoplasms.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Care Philosophy: I prefer to look at my interactions with my patients as a partnership. We work together to improve their health, cure their cancer, manage their reflux, or make their breathing better. I strongly believe that patients need to be an active participant in their care, and the first step of that is making sure they understand what the clinical situation is, what I propose as a treatment plan,and what their expectations can be going forward. Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Biography: Dr. Hershman is an American Cancer Society Professor of Medicine and Epidemiology and is the Director of Breast Oncology and co-leader of the Cancer Population Science program at the Herbert Irving Comprehensive Cancer Center at Columbia University. She completed her medical degree at the Albert Einstein College of Medicine, and completed her internal medicine and oncology fellowship training at Columbia University Medical Center, where she served as Chief Resident. During that time she completed a Master's degree in Biostatistics at the Mailman School of Public Health. She has developed nationally recognized expertise in breast cancer treatment, prevention, and survivorship. Dr. Hershman has also developed a comprehensive multidisciplinary program to study ways of improving cancer care delivery (CCD), reducing disparities and designing studies to improve the quality of life and quality of care in breast cancer survivors. She has received funding from the American Society of Clinical Oncology, American Cancer Society, Department of Defense, Breast Cancer Research Foundation, PCORI, and the National Cancer Institute. She currently has mentored numerous faculty members who have been granted mentored career development awards, and has received the Women Who Conquer Cancer Mentorship Award and the CUIMC Mentor of the Year Award. Dr. Hershman has published over 450 scientific articles and has received several awards including the highly prestigious Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology, the Advanced Medical Achievement Award from the Avon Foundation and a Giants in Cancer Care Award. She has several national leadership roles in oncology. As vice chair of the SWOG Cancer Research Network she oversees the NCI's Community Oncology Research Programs (NCORP) research portfolio, which includes prevention and epidemiology, cancer care delivery, symptom control and quality of life, and survivorship trials. Within ASCO she was selected to participate in the first Leadership Development Program and has been the Chair of the Grants Selection Committee, Chair of the ASCO Quality Care Symposium and has been a member of multiple committees and task-forces. She is on the editorial board for the Journal of Clinical Oncology and is an Associate Editor at the Journal of the National Cancer Institute.